All results
10 results for phase 2 multi center double blind randomized dose ranging placebo controlled study
-
Clinical Trials
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…
-
Clinical Trials
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of…
-
Clinical Trials
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…
-
Clinical Trials
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…
-
Clinical Trials
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
-
Clinical Trials
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…
-
Clinical Trials
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
-
Clinical Trials
This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that…
-
Clinical Trials
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…
-
News, Stories & Blog
Part 2 of our “Year in Review” focuses on the hospitals, research institutes and centers that are part of the UF Health family: UF Health Cancer Center UF…